Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | PPIA | P62937 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 5/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3290310 | 0.77 | MEN1 (0.56) | NOS1PPIAMEN1KMT2ANOS3 | |
| SCHEMBL22879358 | 0.76 | ANPEP (0.53) | NOS1PARP1KDM1AHTR2A | |
| SCHEMBL21311751 | 0.75 | PPIA (0.40) | NOS1PPIAMEN1KMT2AESR1 | |
| SCHEMBL7544039 | 0.75 | NOS1 (0.42) | NOS1PPIAMEN1KMT2AESR1 | |
| SCHEMBL12813351 | 0.75 | PPIA (0.47) | NOS1PPIAMEN1KMT2AESR1 | |
| SCHEMBL8894478 | 0.75 | PPIA (0.40) | NOS1PPIAMEN1KMT2AESR1 | |
| SCHEMBL6240869 | 0.73 | ADRA2A (0.43) | HTR2A | |
| SCHEMBL14577672 | 0.72 | PPIA (0.41) | NOS1PPIAMEN1KMT2AESR1 | |
| SCHEMBL22625621 | 0.71 | ESR1 (0.45) | NOS1PPIAMEN1KMT2AESR1 | |
| SCHEMBL11619641 | 0.71 | PPIA (0.38) | NOS1PPIAMEN1KMT2AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575106-B2 | Cosmetic uses of modified stressed yeast extracts and related compositions | AVON PRODUCTS, INC. (US) | 2013-11-05 | — | — | US | claimed |
| EP-2473183-A2 | COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS | Avon Products, Inc. (US) | 2012-07-11 | — | — | EP | claimed |
| US-20110052517-A1 | Cosmetic Uses of Modified Stressed Yeast Extracts and Related Compositions | Avon Place (US) | 2011-03-03 | — | — | US | claimed |
| WO-2011025635-A2 | COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS | AVON PRODUCTS, INC. (US) | 2011-03-03 | — | — | WO | claimed |
| EP-2473183-B1 | COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS | AVON PROD INC (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2890359-B1 | DICKKOPF-1 EXPRESSION MODULATING COMPOSITIONS AND USES THEREOF | AVON PROD INC (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2890359-A1 | DICKKOPF-1 EXPRESSION MODULATING COMPOSITIONS AND USES THEREOF | Avon Products, Inc. (US) | 2015-07-08 | — | — | EP | disclosed |
| US-9023327-B2 | DICKKOPF-1 expression modulating compositions and uses thereof | AVON PRODUCTS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140065086-A1 | Dickkopf-1 Expression Modulating Compositions and Uses Thereof | AVON PRODUCTS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2014035401-A1 | DICKKOPF-1 EXPRESSION MODULATING COMPOSITIONS AND USES THEREOF | AVON PRODUCTS, INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-8575106-B2 | Cosmetic uses of modified stressed yeast extracts and related compositions | AVON PRODUCTS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2473183-A2 | COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS | Avon Products, Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20110052517-A1 | Cosmetic Uses of Modified Stressed Yeast Extracts and Related Compositions | Avon Place (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2011025635-A2 | COSMETIC USES OF MODIFIED STRESSED YEAST EXTRACTS AND RELATED COMPOSITIONS | AVON PRODUCTS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20070105752-A1 | Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma | NEW YORK UNIVERSITY MEDICAL CENTER | 2007-05-10 | — | — | US | disclosed |
| WO-2006084005-A2 | EMERGENCE OF A R-TYPE CA2+CHANNEL(CAV2.3) CONTRIBUTES TO CEREBRAL ARTERY CONSTRICTION FOLLOWING SUBARACHNOID HEMORRHAGE | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20020045191-A1 | Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma | NEW YORK UNIVERSITY | 2002-04-18 | — | — | US | disclosed |
| US-5081304-A | Diagnosis of neurodegenerative disorders | WARNER-LAMBERT COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| US-4960815-A | CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 1990-10-02 | — | — | US | disclosed |